



SAFETY DATA SHEET

Revision date: 21-Aug-2018

Version: 1.0

Page 1 of 14

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Trimethoprim and Sulfamethoxazole Oral Suspension

Trade Name: SEPTRA, PARKAZOLE; TRIZODAL

Chemical Family: Not determined

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used as antibiotic agent

Details of the Supplier of the Safety Data Sheet

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-800-879-3477

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

Emergency telephone number:
International CHEMTREC (24 hours): +1-703-527-3887

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification

Reproductive Toxicity: Category 2

Label Elements

Signal Word: Warning
Hazard Statements: H361d - Suspected of damaging the unborn child

Precautionary Statements: P201 - Obtain special instructions before use
P202 - Do not handle until all safety precautions have been read and understood
P281 - Use personal protective equipment as required
P308 + P313 - IF exposed or concerned: Get medical attention/advice
P405 - Store locked up
P501 - Dispose of contents/container in accordance with all local and national regulations



SAFETY DATA SHEET

Material Name: Trimethoprim and Sulfamethoxazole Oral
Suspension
Revision date: 21-Aug-2018

Page 2 of 14

Version: 1.0

Other Hazards An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

Note: This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Trimethoprim	738-70-5	212-006-2	Acute Tox.3 (H301) Repr. Tox.2 (H361d)	0.8-1.6
Sulfamethoxazole	723-46-6	211-963-3	Repr. 2; H361d	4-8
Glycerin, USP	56-81-5	200-289-5	Not Listed	*
Alcohol	64-17-5	200-578-6	Flam. Liq. 2 (H225)	<1.0
Microcrystalline cellulose	9004-34-6	232-674-9	Not Listed	*
Citric acid	77-92-9	201-069-1	Eye Irrit. 2A (H319)	*

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
FD & C Red No. 40	25956-17-6	247-368-0	Not Listed	*
Sodium benzoate	532-32-1	208-534-8	Not Listed	*
Sorbitol	6706-59-8	Not Listed	Not Listed	*
Flavor	NOT ASSIGNED	Not Listed	Not Listed	*
FD&C yellow No.6 aluminum lake	15790-07-5	239-888-1	Not Listed	*
FD & C Blue No. 1	3844-45-9	223-339-8	Not Listed	*
Saccharin	81-07-2	201-321-0	Not Listed	*
Carboxymethylcellulose sodium	9004-32-4	Not Listed	Not Listed	*
Polysorbate 80	9005-65-6	500-019-9	Not Listed	*
Methylparaben	99-76-3	202-785-7	Not Listed	*

Additional Information: * Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.
In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

SAFETY DATA SHEET

Material Name: Trimethoprim and Sulfamethoxazole Oral
Suspension
Revision date: 21-Aug-2018

Page 3 of 14

Version: 1.0

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO₂, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters

During all firefighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of the spill if it is safe to do so. Absorb spills with non-combustible absorbent material and transfer into a labeled container for disposal.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Cleanup operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Specific end use(s): Pharmaceutical drug product

SAFETY DATA SHEET

Material Name: Trimethoprim and Sulfamethoxazole Oral
Suspension
Revision date: 21-Aug-2018

Page 4 of 14

Version: 1.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

Trimethoprim

Pfizer OEL TWA-8 Hr: 100µg/m³

Glycerin, USP

Australia TWA	10 mg/m ³
Belgium OEL - TWA	10 mg/m ³
Czech Republic OEL - TWA	10 mg/m ³
Estonia OEL - TWA	10 mg/m ³
Finland OEL - TWA	20 mg/m ³
France OEL - TWA	10 mg/m ³
Germany (DFG) - MAK	200 mg/m ³
Greece OEL - TWA	10 mg/m ³
Ireland OEL - TWAs	10 mg/m ³
OSHA - Final PELs - TWAs:	15 mg/m ³
Poland OEL - TWA	10 mg/m ³
Portugal OEL - TWA	10 mg/m ³
Spain OEL - TWA	10 mg/m ³
Switzerland OEL - TWAs	50 mg/m ³

Alcohol

ACGIH Threshold Limit Value (STEL)	1000 ppm
Australia TWA	1000 ppm
	1880 mg/m ³
Austria OEL - MAKs	1000 ppm
	1900 mg/m ³
Belgium OEL - TWA	1000 ppm
	1907 mg/m ³
Bulgaria OEL - TWA	1000 mg/m ³
Czech Republic OEL - TWA	1000 mg/m ³
Denmark OEL - TWA	1000 ppm
	1900 mg/m ³
Estonia OEL - TWA	500 ppm
	1000 mg/m ³
Finland OEL - TWA	1000 ppm
	1900 mg/m ³
France OEL - TWA	1000 ppm
	1900 mg/m ³
Germany - TRGS 900 - TWAs	500 ppm
	960 mg/m ³
Germany (DFG) - MAK	500 ppm
	960 mg/m ³
Greece OEL - TWA	1000 ppm
	1900 mg/m ³
Hungary OEL - TWA	1900 mg/m ³
Latvia OEL - TWA	1000 mg/m ³
Lithuania OEL - TWA	500 ppm
	1000 mg/m ³
Netherlands OEL - TWA	260 mg/m ³

SAFETY DATA SHEET

Material Name: Trimethoprim and Sulfamethoxazole Oral
Suspension
Revision date: 21-Aug-2018

Page 5 of 14

Version: 1.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

OSHA - Final PELs - TWAs:	1000 ppm 1900 mg/m ³
Poland OEL - TWA	1900 mg/m ³
Portugal OEL - TWA	1000 ppm
Romania OEL - TWA	1000 ppm 1900 mg/m ³
Russia OEL - TWA	1000 mg/m ³
Slovakia OEL - TWA	500 ppm 960 mg/m ³
Slovenia OEL - TWA	1000 ppm 1900 mg/m ³
Sweden OEL - TWAs	500 ppm 1000 mg/m ³
Switzerland OEL -TWAs	500 ppm 960 mg/m ³
Vietnam OEL - TWAs	1000 mg/m ³

Microcrystalline cellulose

ACGIH Threshold Limit Value (TWA)	10 mg/m ³
Australia TWA	10 mg/m ³
Belgium OEL - TWA	10 mg/m ³
Estonia OEL - TWA	10 mg/m ³
France OEL - TWA	10 mg/m ³
Ireland OEL - TWAs	10 mg/m ³ 4 mg/m ³
Latvia OEL - TWA	2 mg/m ³
OSHA - Final PELs - TWAs:	15 mg/m ³
Portugal OEL - TWA	10 mg/m ³
Romania OEL - TWA	10 mg/m ³
Russia OEL - TWA	6 mg/m ³
Spain OEL - TWA	10 mg/m ³
Switzerland OEL -TWAs	3 mg/m ³
Vietnam OEL - TWAs	10 mg/m ³ 5 mg/m ³

Sulfamethoxazole

Pfizer Occupational Exposure Band (OEB): OEB 1 (control exposure to the range of 1000ug/m³ to 3000ug/m³)

Exposure Controls

Engineering Controls:

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal Protective Equipment:

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

Hands:

Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.)

SAFETY DATA SHEET

Material Name: Trimethoprim and Sulfamethoxazole Oral
Suspension
Revision date: 21-Aug-2018

Page 6 of 14

Version: 1.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Eyes: Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.)

Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.)

Respiratory protection: Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.)

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Liquid	Color:	No data available.
Odor:	No data available.	Odor Threshold:	No data available.
Molecular Formula:	Mixture	Molecular Weight:	Mixture

Solvent Solubility:	No data available
Water Solubility:	No data available
pH:	No data available.
Melting/Freezing Point (°C):	No data available
Boiling Point (°C):	No data available.
Partition Coefficient: (Method, pH, Endpoint, Value)	

FD & C Red No. 40

No data available

Sulfamethoxazole

No data available

Trimethoprim

Measured NA Log P 0.38

Alcohol

No data available

Methylparaben

No data available

Sodium benzoate

No data available

Carboxymethylcellulose sodium

No data available

Citric acid

No data available

FD&C yellow No.6 aluminum lake

No data available

FD & C Blue No. 1

No data available

Flavor

No data available

Polysorbate 80

No data available

Saccharin

No data available

Sorbitol

No data available

SAFETY DATA SHEET

Material Name: Trimethoprim and Sulfamethoxazole Oral
Suspension
Revision date: 21-Aug-2018

Page 7 of 14

Version: 1.0

9. PHYSICAL AND CHEMICAL PROPERTIES

Glycerin, USP

No data available

Microcrystalline cellulose

No data available

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s): No data available

Vapor Pressure (kPa): No data available

Vapor Density (g/ml): No data available

Relative Density: No data available

Viscosity: No data available

Flammability:

Autoignition Temperature (Solid) (°C): No data available

Flammability (Solids): No data available

Flash Point (Liquid) (°C): No data available

Upper Explosive Limits (Liquid) (% by Vol.): No data available

Lower Explosive Limits (Liquid) (% by Vol.): No data available

10. STABILITY AND REACTIVITY

Reactivity: No data available

Chemical Stability: Stable under normal conditions of use.

Possibility of Hazardous Reactions

Oxidizing Properties: No data available

Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.

Incompatible Materials: As a precautionary measure, keep away from strong oxidizers

Hazardous Decomposition Products: No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information: The information included in this section describes the potential hazards of the individual ingredients.

Short Term: May be harmful if swallowed. (based on animal data)

Long Term: Animal studies have shown a potential to cause adverse effects on the fetus.

Known Clinical Effects: Adverse effects associated with therapeutic use include nausea, diarrhea, blood cell changes, muscle pain, skin rash, Stevens Johnson Syndrome (epidermal necrosis and exfoliative dermatitis), kidney toxicity (nephrotoxicity). Clinical use has resulted in changes in electrolytes and/or blood chemistry changes. Individuals sensitive to this material or other materials in its chemical class may develop allergic reactions.

Acute Toxicity: (Species, Route, End Point, Dose)

Sulfamethoxazole

Rat Oral LD 50 6370

Mouse Oral LD 50 2650

Rat Intraperitoneal LD 50 2690

Mouse Intraperitoneal LD 50 2300

Trimethoprim

SAFETY DATA SHEET

Material Name: Trimethoprim and Sulfamethoxazole Oral
Suspension

Page 8 of 14

Revision date: 21-Aug-2018

Version: 1.0

11. TOXICOLOGICAL INFORMATION

Rat Oral LD50 200 mg/kg
Rat Sub-tenon injection (eye) LD50 500mg/kg
Mouse Oral LD50 2764mg/kg
Mouse Intravenous LD50 200mg/kg
Mouse Intraperitoneal LD50 1870mg/kg

Alcohol

Rat Inhalation LC50 20,000mg/L

Sodium benzoate

Rat Oral LD50 4,070 mg/kg
Mouse Oral LD50 1600mg/kg

Carboxymethylcellulose sodium

Mouse Oral LD50 > 27,000 mg/kg
Rat Oral LD50 27,000 mg/kg
Rabbit Dermal LD50 > 2000 mg/kg

Citric acid

Rat Oral LD50 3000 mg/kg

Polysorbate 80

Rat Intravenous LD 50 1790 mg/kg
Mouse Oral LD 50 25 g/kg

Glycerin, USP

Mouse Oral LD50 4090 mg/kg
Rat Oral LD50 12.6 g/kg
Rabbit Dermal LD50 > 10 g/kg
Rat Inhalation LC50 1hr > 570 mg/m³
Rat Dermal LD 50 > 21.9 g/kg

Microcrystalline cellulose

Rat Oral LD50 > 5000 mg/kg
Rabbit Dermal LD50 > 2000 mg/kg

Acute Toxicity Comments:

A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Alcohol

Eye Irritation Rabbit Severe

Citric acid

Eye Irritation Rabbit Severe
Skin Irritation Rabbit Mild

SAFETY DATA SHEET

Material Name: Trimethoprim and Sulfamethoxazole Oral
Suspension
Revision date: 21-Aug-2018

Page 9 of 14

Version: 1.0

11. TOXICOLOGICAL INFORMATION

Glycerin, USP

Eye Irritation Rabbit Mild

Microcrystalline cellulose

Skin Irritation Rabbit Non-irritating

Eye Irritation Rabbit Non-irritating

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Sodium benzoate

10 Day(s) Rat Oral 27370 mg/kg LOEL Liver, Blood

10 Day(s) Mouse Oral 45 g/kg LOEL Liver, Kidney, Blood, Ureter, Bladder

Carboxymethylcellulose sodium

13 Week(s) Rat Oral 227 g/kg LOEL Liver, Kidney, Ureter, Bladder

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Sulfamethoxazole

Embryo / Fetal Development Rat Oral 512 mg/kg/day NOEL Teratogenic

Reproductive & Fertility Rat Oral 350 mg/kg/day NOEL No effects at maximum dose

Trimethoprim

Reproductive & Fertility-Males Rat Oral 70 mg/kg/day NOEL Fertility

Reproductive & Fertility - Females Rat Oral 14 mg/kg/day NOEL Fertility

Embryo / Fetal Development Rabbit Oral 30 mg/kg LOEL Embryotoxicity

Embryo / Fetal Development Rat Oral 200 mg/kg LOEL Maternal Toxicity, Teratogenic

Embryo / Fetal Development Mouse Oral 70 mg/kg NOEL Not Teratogenic

Sodium benzoate

Embryo / Fetal Development Rat Oral 44 g/kg LOEL Developmental toxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Sulfamethoxazole

Bacterial Mutagenicity (Ames) *Salmonella* Negative

In Vivo Chromosome Aberration Human Lymphocytes Negative

In Vitro Chromosome Aberration Human Lymphocytes Negative

Trimethoprim

Bacterial Mutagenicity (Ames) *Salmonella*, *E. coli* Negative

In Vitro Chromosome Aberration Chinese Hamster Ovary (CHO) cells Negative

In Vitro Chromosome Aberration Human Lymphocytes Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Sulfamethoxazole

60 Week(s) Rat Oral 60 LOEL Tumors, Thyroid

SAFETY DATA SHEET

Material Name: Trimethoprim and Sulfamethoxazole Oral
Suspension
Revision date: 21-Aug-2018

Page 10 of 14

Version: 1.0

11. TOXICOLOGICAL INFORMATION

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA. Ethanol has been shown to be carcinogenic in long-term studies only when consumed as alcoholic beverage

Sulfamethoxazole
IARC: Group 3 (Not Classifiable)

Alcohol
IARC: Group 1 (Carcinogenic to Humans)

FD & C Blue No. 1
IARC: Group 3 (Not Classifiable)

Saccharin
IARC: Group 3 (Not Classifiable)

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.

Toxicity:
Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Trimethoprim
Daphnia magna (Water Flea) OECD LC50 48 Hours 141 mg/L

Glycerin, USP
Oncorhynchus mykiss (Rainbow Trout) LC50 96 Hours 50 mg/L
Daphnia magna (Water Flea) EC50 24 Hours >500 mg/L

Persistence and Degradability: No data available

Bio-accumulative Potential:
Partition Coefficient: (Method, pH, Endpoint, Value)

Trimethoprim
Measured NA Log P 0.38

Mobility in Soil: No data available

SAFETY DATA SHEET

Material Name: Trimethoprim and Sulfamethoxazole Oral
Suspension
Revision date: 21-Aug-2018

Page 11 of 14

Version: 1.0

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Trimethoprim

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 4
EU EINECS/ELINCS List	212-006-2

Sulfamethoxazole

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 4
EU EINECS/ELINCS List	211-963-3

FD & C Red No. 40

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	247-368-0

SAFETY DATA SHEET

Material Name: Trimethoprim and Sulfamethoxazole Oral
Suspension
Revision date: 21-Aug-2018

Page 12 of 14

Version: 1.0

15. REGULATORY INFORMATION

Sodium benzoate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	208-534-8

Glycerin, USP

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex V - Exemptions from the obligations of Register:	Present if not chemically modified, except they meet the criteria for classification as dangerous according to Directive 67/548/EEC, except those only classified as flammable [R10], as a skin irritant [R38] or as an eye irritant [R36], except they are persistent, bio accumulative, and toxic or very persistent and very bio accumulative in accordance with the criteria set out in Annex XIII, except they were identified in accordance with Article 59[1] at least two years previously as substances giving rise to an equivalent level of concern
EU EINECS/ELINCS List	200-289-5

Alcohol

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	carcinogen 4/29/2011 in alcoholic beverages developmental toxicity 10/1/1987 in alcoholic beverages
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	200-578-6

Sorbitol

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	Not Listed

Flavor

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	Not Listed

FD&C yellow No.6 aluminum lake

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	239-888-1

FD & C Blue No. 1

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed

SAFETY DATA SHEET

Material Name: Trimethoprim and Sulfamethoxazole Oral
 Suspension
 Revision date: 21-Aug-2018

Page 13 of 14

Version: 1.0

15. REGULATORY INFORMATION

Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	223-339-8

Saccharin

CERCLA/SARA 313 Emission reporting	1.0 %
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	201-321-0

Carboxymethylcellulose sodium

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed

Microcrystalline cellulose

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	232-674-9

Polysorbate 80

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	500-019-9

Methylparaben

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	202-785-7

Citric acid

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	201-069-1

16. OTHER INFORMATION

Text of CLP/GHS Classification abbreviations mentioned in Section 3

SAFETY DATA SHEET

Material Name: Trimethoprim and Sulfamethoxazole Oral
Suspension

Page 14 of 14

Revision date: 21-Aug-2018

Version: 1.0

Acute toxicity, oral-Cat.3; H301 - Toxic if swallowed
Reproductive toxicity-Cat.2; H361d - Suspected of damaging the unborn child

Data Sources: Safety data sheets for individual ingredients. Publicly available toxicity information.

Reasons for Revision: New data sheet.

Revision date: 21-Aug-2018

Product Stewardship Hazard Communication

Prepared by: Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet